Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.34 |
| ▸ | GAS6 | Q14393 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507825 | 0.95 | MERTK (0.46) | MERTKHTTPPARGMEN1GABBR2 | |
| SCHEMBL22860693 | 0.94 | MERTK (0.46) | MERTKHTTPPARGMEN1GABBR2 | |
| SCHEMBL2622288 | 0.94 | GABBR2 (0.47) | MERTKHTTPPARGMEN1GABBR2 | |
| SCHEMBL4711841 | 0.93 | GABBR2 (0.46) | MERTKHTTPPARGMEN1GABBR2 | |
| SCHEMBL4713140 | 0.93 | GABBR2 (0.46) | MERTKHTTPPARGMEN1GABBR2 | |
| SCHEMBL29507857 | 0.87 | HTT (0.44) | MERTKHTTPPARGMEN1GABBR2 | |
| SCHEMBL26090940 | 0.85 | MERTK (0.47) | MERTKHTTPPARGMEN1GABBR2 | |
| SCHEMBL31153372 | 0.85 | MERTK (0.43) | MERTKHTTMEN1GABBR2CYP1A2 | |
| SCHEMBL19857335 | 0.85 | MERTK (0.43) | MERTKHTTMEN1GABBR2CYP1A2 | |
| SCHEMBL28734723 | 0.84 | HTT (0.40) | MERTKHTTPPARGMEN1GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137393-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASES 2, 4, AND 6 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3733184-B1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733184-A1 | PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Icahn School of Medicine at Mount Sinai (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| EP-2968331-B1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL MED MOUNT SINAI (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2014151682-A1 | PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014144737-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-0964864-B1 | PYRIDO 2,3-D PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1806348-A2 | Pyrido (2,3-D)Pyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| US-6498163-B1 | POTENT INHIBITORS OF CYCLIN-DEPENDENT KINASES AND GROWTH FACTOR MEDIATED KINASES; CANCER, RESTENOSIS, ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2002-12-24 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0964864-A2 | PYRIDO 2,3-D] PYRIMIDINES AND 4-AMINOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998033798-A2 | PYRIDO[2,3-D]PYRIMIDINES AND 4-AMINO-PYRIMIDINES AS INHIBITORS OF CELL PROLIFERATION | WARNER LAMBERT COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | MERTK 1128/4885HTT 1933/4885PPARG 785/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | MERTK 4082/4885HTT 89/4885PPARG 348/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | MERTK 4082/4885HTT 89/4885PPARG 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.